Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

GT Biopharma Inc (GTBP)

GT Biopharma Inc (GTBP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 155,080
  • Shares Outstanding, K 21,128
  • Annual Sales, $ 0 K
  • Annual Income, $ -28,300 K
  • 60-Month Beta 0.34
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.88
Trade GTBP with:

Options Overview Details

View History
  • Implied Volatility 187.78%
  • Historical Volatility 82.59%
  • IV Percentile 94%
  • IV Rank 31.91%
  • IV High 394.79% on 07/19/21
  • IV Low 90.75% on 06/25/21
  • Put/Call Vol Ratio 2.14
  • Today's Volume 66
  • Volume Avg (30-Day) 241
  • Put/Call OI Ratio 2.75
  • Today's Open Interest 1,986
  • Open Int (30-Day) 987

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.28
  • Number of Estimates 3
  • High Estimate -0.20
  • Low Estimate -0.33
  • Prior Year -0.68
  • Growth Rate Est. (year over year) +58.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.85 +4.76%
on 09/21/21
9.12 -21.27%
on 09/01/21
-0.39 (-5.15%)
since 08/20/21
3-Month
6.85 +4.76%
on 09/21/21
17.11 -58.04%
on 06/22/21
-9.41 (-56.72%)
since 06/21/21
52-Week
2.55 +181.57%
on 11/24/20
19.73 -63.61%
on 06/14/21
+4.39 (+157.53%)
since 09/21/20

Most Recent Stories

More News
GT BioPharma's Next Generation Camelid TriKE® Nanobody Platform Highlighted at ESMO Congress 2021

/PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer...

GTBP : 7.18 (-2.18%)
OXIS International Inc. (GTBP) Moves to Buy: Rationale Behind the Upgrade

OXIS International Inc. (GTBP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GTBP : 7.18 (-2.18%)
GT Biopharma Announces Updated Positive Safety Data From Phase 1 GTB-3550 Monotherapy TriKE™ Trial an Investigational Immunotherapy for Refractory Cancers to be Presented at ESMO Congress 2021

/PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer...

GTBP : 7.18 (-2.18%)
GT Biopharma Advances GTB-3650, a Second-Generation Tri-Specific Killer Engager -TriKE®, Into IND-Enabling Studies

/PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer...

GTBP : 7.18 (-2.18%)
GT Biopharma Announces Issuance of Two New Patents Covering TriKE® Platform Technologies

/PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer...

GTBP : 7.18 (-2.18%)
GT Biopharma to Present at Upcoming September Investor Conferences

/PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager,...

GTBP : 7.18 (-2.18%)
Stocks Remained Hot in August

Stocks Remained Hot in August

FLXN : 6.20 (+1.47%)
ABM : 44.06 (-1.08%)
ANF : 37.70 (+1.78%)
PTON : 100.92 (+0.19%)
ADSK : 283.19 (-0.14%)
AZEK : 38.65 (-1.48%)
INTU : 555.25 (+0.15%)
JD : 73.50 (-0.88%)
STNE : 40.15 (-0.74%)
GTBP : 7.18 (-2.18%)
CCRN : 20.31 (+2.27%)
APPS : 65.51 (+3.70%)
NASDAQ, S&P Close at New Records on Fourth Day of Gains

NASDAQ, S&P Close at New Records on Fourth Day of Gains

BW : 6.04 (-0.82%)
OCSL : 7.17 (+1.56%)
VOLT : 3.38 (+1.20%)
SONO : 36.71 (-0.22%)
GTBP : 7.18 (-2.18%)
MAN : 106.54 (-1.54%)
KMB : 134.50 (-0.01%)
ETN : 154.59 (-1.22%)
FLEX : 17.71 (-0.39%)
ON : 47.68 (+0.02%)
TEX : 42.11 (-5.14%)
CB : 175.80 (-1.17%)
YY : 53.00 (+0.30%)
JD : 73.50 (-0.88%)
AMZN : 3,343.63 (-0.36%)
HTHT : 45.99 (+1.25%)
GOOS : 36.93 (+1.43%)
AZEK : 38.65 (-1.48%)
BBY : 106.89 (+0.21%)
CRM : 257.97 (-0.10%)
ULTA : 369.84 (+0.03%)
DKS : 132.58 (+0.51%)
WSM : 184.73 (+0.99%)
GT Biopharma Announces the Promotion of Dr. Gregory Berk to President of Research & Development and Chief Medical Officer

/PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager,...

GTBP : 7.18 (-2.18%)
GT Biopharma Provides Second Quarter 2021 Business Update

/PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary...

GTBP : 7.18 (-2.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

GT Biopharma Inc. is an immuno-oncology company. It discovers, develops and commercializes drugs of therapeutic molecules for the treatment of cancer, myeloma, osteolytic lesions and other unmet medical needs. GT Biopharma Inc., formerly known as OXIS International Inc., is based in Tampa, Florida.

See More

Key Turning Points

3rd Resistance Point 8.16
2nd Resistance Point 7.84
1st Resistance Point 7.51
Last Price 7.18
1st Support Level 6.85
2nd Support Level 6.53
3rd Support Level 6.20

See More

52-Week High 19.73
Fibonacci 61.8% 13.17
Fibonacci 50% 11.14
Fibonacci 38.2% 9.11
Last Price 7.18
52-Week Low 2.55

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar